ABSTRACTRifabutin, used to treat HIV-infected tuberculosis, shows highly variable drug exposure, complicating dosing. Effects ofSLCO1B1polymorphisms on rifabutin pharmacokinetics were investigated in 35 African HIV-infected tuberculosis patients after multiple doses. Nonlinear mixed-effects modeling found that influential covariates for the pharmacokinetics were weight, sex, and a 30% increased bioavailability among heterozygous carriers ofSLCO1B1rs1104581 (previously associated with low rifampin concentrations). Larger studies are needed to understand the complex interactions of host genetics in HIV-infected tuberculosis patients. (This study has been registered at ClinicalTrials.gov under registration no. NCT00640887.)
Developent of stem taper equation using nonlinear mixed-effects modeling approach for Taurus fir
